0001127602-23-008575.txt : 20230306 0001127602-23-008575.hdr.sgml : 20230306 20230303111434 ACCESSION NUMBER: 0001127602-23-008575 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230301 FILED AS OF DATE: 20230303 DATE AS OF CHANGE: 20230303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Febbo Phillip G. CENTRAL INDEX KEY: 0001649245 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35406 FILM NUMBER: 23702287 MAIL ADDRESS: STREET 1: C/O GENOMIC HEALTH, INC. STREET 2: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ILLUMINA, INC. CENTRAL INDEX KEY: 0001110803 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 330804655 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5200 ILLUMINA WAY CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 8582024500 MAIL ADDRESS: STREET 1: 5200 ILLUMINA WAY CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: ILLUMINA INC DATE OF NAME CHANGE: 20000331 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2023-03-01 0001110803 ILLUMINA, INC. ILMN 0001649245 Febbo Phillip G. 5200 ILLUMINA WAY SAN DIEGO CA 92122 1 SVP Chief Medical Officer Common Stock 2023-03-01 4 A 0 7556 0 A 14786 D Performance Shares 2023-03-01 4 A 0 3023 0 A 2024-12-29 Common Stock 3023 3023 D Performance Shares 2023-03-01 4 A 0 4534 0 A 2025-12-28 Common Stock 4534 4534 D Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2023, November 5, 2024, November 5, 2025, and November 5, 2026, subject to awardee's continuing status as a service provider on such dates. Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 28, 2025. The number of shares issued will range from 0% to 175% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 28, 2025, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. /s/ Robert Maynes for Phillip Febbo 2023-03-03